Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Luminex was bullish about its molecular diagnostics business, Natera outlined its work with pharmaceutical firms, and Oxford discussed its plans in TB and tick-borne diseases.
The firm said that it expects to report a 12 percent year-over-year increase in molecular diagnostics product revenues, driven by Verigene and Aries placements.
The settlement requires that Curiox refrain from saying that one of its products has equivalent or better sensitivity and reproducibility than a Luminex system.
The assay is part of a respiratory testing menu that includes assays for Bordetella and Flu A/B & RSV, and NxTAG and Verigene respiratory pathogen panels.
Luminex said that its total sample-to-answer molecular product revenue of $11.9 million grew 55 percent from $7.7 million in the third quarter of 2016.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.